Skip to main content

Table 2 Comparison of the antimicrobial susceptibility of community-acquired (CA) and healthcare-associated (HCA) Klebsiella pneumoniae bloodstream infection ( Kp BSI)

From: Differences in characteristics between healthcare-associated and community-acquired infection in community-onset Klebsiella pneumoniae bloodstream infection in Korea

Antibiotics

CA-KpBSI (n = 240)

HCA-KpBSI (n = 313)

p

(Non-susceptible/T (%))

(Non-susceptible/T (%))

Ciprofloxacin

12/240 (5.0)

36/313 (11.5)

0.007

Extended-spectrum cephalosporin

8/240 (3.3)

29/313 (9.3)

0.006

  Cefotaxime

8/240 (3.3)

25/313 (8.0)

0.022

  Ceftazidime

6/240 (2.5)

25/313 (8.0)

0.005

ESBL-productiona

2/237 (0.8)

16/310 (5.2)

0.006

Piperacillin plus tazobactam

6/239 (2.5)

19/311 (6.1)

0.045

Aztreonam

5/175 (2.9)

26/253 (11.1)

0.004

Imipenem

1/240 (0.4)

1/313 (0.3)

1.000

Amikacin

7/240 (2.9)

17/313 (5.4)

0.150

Gentamicin

6/240 (2.5)

22/313 (7.0)

0.016

Tobramycin

7/177 (4.0)

26/253 (10.3)

0.015

  1. Data indicate number of non-susceptible isolates/total number of tested isolates (%).
  2. T, total number of tested isolates; ESBL, extended-spectrum beta-lactamase.
  3. a 5 isolates among the CA-KpBSI were available for ESBL confirmatory tests and 14 among the HCA-KpBSI.